Key Insights

Highlights

Success Rate

78% trial completion

Published Results

34 trials with published results (19%)

Research Maturity

88 completed trials (50% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

14.3%

25 terminated out of 175 trials

Success Rate

77.9%

-8.6% vs benchmark

Late-Stage Pipeline

6%

10 trials in Phase 3/4

Results Transparency

39%

34 of 88 completed with results

Key Signals

34 with results78% success25 terminated

Data Visualizations

Phase Distribution

138Total
Not Applicable (40)
Early P 1 (7)
P 1 (52)
P 2 (29)
P 3 (8)
P 4 (2)

Trial Status

Completed88
Recruiting29
Terminated25
Active Not Recruiting11
Withdrawn6
Not Yet Recruiting6

Trial Success Rate

77.9%

Benchmark: 86.5%

Based on 88 completed trials

Clinical Trials (175)

Showing 20 of 20 trials
NCT07416188Phase 1Not Yet Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

NCT07326566Phase 2Recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT03115398Not ApplicableCompletedPrimary

A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery

NCT02800486Phase 2Recruiting

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

NCT07374692Not ApplicableRecruiting

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

NCT02851706CompletedPrimary

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

NCT07493447Early Phase 1Not Yet Recruiting

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT02852655Phase 1Active Not RecruitingPrimary

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

NCT04899908Phase 2Active Not RecruitingPrimary

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT02375841Active Not RecruitingPrimary

Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers

NCT04075305Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT03152318Phase 1Active Not Recruiting

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

NCT07210632Early Phase 1Not Yet RecruitingPrimary

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT06058988Phase 2RecruitingPrimary

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

NCT04268979Not ApplicableCompletedPrimary

Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator

NCT04689048Phase 1Recruiting

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04478279Phase 1Active Not Recruiting

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT07398066Not ApplicableNot Yet Recruiting

DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial)

NCT04173104Early Phase 1Completed

PET and MRI Imaging of Brain Tumors Using [18F]PARPi

NCT05366881RecruitingPrimary

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Scroll to load more

Research Network

Activity Timeline